Wilson Asset Management International PTY Ltd. Boosts Stake in Masimo Corporation $MASI

Wilson Asset Management International PTY Ltd. raised its position in shares of Masimo Corporation (NASDAQ:MASI) by 44.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 39,437 shares of the medical equipment provider’s stock after buying an additional 12,203 shares during the quarter. Masimo comprises approximately 1.3% of Wilson Asset Management International PTY Ltd.’s holdings, making the stock its 23rd largest position. Wilson Asset Management International PTY Ltd.’s holdings in Masimo were worth $5,129,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Cardinal Capital Management grew its position in Masimo by 1.3% during the fourth quarter. Cardinal Capital Management now owns 21,462 shares of the medical equipment provider’s stock valued at $2,791,000 after acquiring an additional 282 shares during the period. Kohmann Bosshard Financial Services LLC purchased a new stake in Masimo during the fourth quarter valued at about $44,000. Torren Management LLC purchased a new stake in Masimo during the fourth quarter valued at about $35,000. M&T Bank Corp grew its position in Masimo by 10.5% during the fourth quarter. M&T Bank Corp now owns 3,324 shares of the medical equipment provider’s stock valued at $432,000 after acquiring an additional 317 shares during the period. Finally, UBS Group AG grew its stake in Masimo by 252.9% during the fourth quarter. UBS Group AG now owns 599,274 shares of the medical equipment provider’s stock worth $77,942,000 after buying an additional 429,474 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on MASI. Wolfe Research downgraded shares of Masimo from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. Raymond James Financial downgraded shares of Masimo from an “outperform” rating to a “market perform” rating in a research note on Friday, March 27th. Stifel Nicolaus set a $180.00 price objective on shares of Masimo in a research note on Tuesday, February 17th. Piper Sandler downgraded shares of Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price objective for the company. in a research note on Tuesday, February 17th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Masimo in a research note on Thursday, January 22nd. Eight research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $181.17.

Masimo Price Performance

Shares of NASDAQ MASI opened at $178.58 on Wednesday. Masimo Corporation has a 1-year low of $125.94 and a 1-year high of $179.00. The business has a 50-day moving average of $177.28 and a 200-day moving average of $154.19. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.49 and a quick ratio of 1.47. The company has a market capitalization of $9.32 billion, a price-to-earnings ratio of -16.94, a PEG ratio of 1.81 and a beta of 1.13.

Masimo Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.